Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Top Cited Papers
- 20 September 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (2), 298-305
- https://doi.org/10.2337/dc19-0641
Abstract
OBJECTIVE To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI. RESULTS EMPA treatment resulted in a placebo-corrected absolute change of −1.8% (95% CI −3.4, −0.2; P = 0.02) and relative change in LFC of −22% (−36, −7; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change −2.5 kg [−3.7, −1.4]; P < 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (−74 mol/L [−108, −42]; P < 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P < 0.001) levels from 0 to 24 weeks. CONCLUSIONS EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.Keywords
Funding Information
- German Diabetes Center
- German Federal Ministry of Health
- German Center for Diabetes Research
- Boehringer Ingelheim
This publication has 41 references indexed in Scilit:
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2013
- Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Topography mapping of whole body adipose tissue using A fully automated and standardized procedureJournal of Magnetic Resonance Imaging, 2010
- Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitisJournal of Hepatology, 2009
- Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical TrialsClinical Gastroenterology and Hepatology, 2008
- Water–fat separation with IDEAL gradient‐echo imagingJournal of Magnetic Resonance Imaging, 2007
- Hepatic lipid accumulation in healthy subjects: A comparative study using spectral fat‐selective MRI and volume‐localized 1H‐MR spectroscopyMagnetic Resonance in Medicine, 2006
- Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general populationAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Missing data: Our view of the state of the art.Psychological Methods, 2002
- Missing data: Our view of the state of the art.Psychological Methods, 2002